Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion

Novartis (NVS) Stock Forecast & Price Target

Novartis logo
$151.05 -5.22 (-3.34%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$153.00 +1.95 (+1.29%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novartis - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
2
Hold
12
Buy
6

Based on 20 Wall Street analysts who have issued ratings for Novartis in the last 12 months, the stock has a consensus rating of "Hold." Out of the 20 analysts, 2 have given a sell rating, 12 have given a hold rating, and 6 have given a buy rating for NVS.

Consensus Price Target

$145.60
-3.61% Downside
According to the 20 analysts' twelve-month price targets for Novartis, the average price target is $145.60. The highest price target for NVS is $180.00, while the lowest price target for NVS is $126.00. The average price target represents a forecasted downside of -3.61% from the current price of $151.05.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for NVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novartis and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NVS Analyst Ratings Over Time

TypeCurrent Forecast
10/25/25 to 10/25/26
1 Month Ago
9/25/25 to 9/25/26
3 Months Ago
7/27/25 to 7/27/26
1 Year Ago
10/25/24 to 10/25/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
2 Buy rating(s)
Hold
12 Hold rating(s)
12 Hold rating(s)
8 Hold rating(s)
4 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
3 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$145.60$148.40$141.20$120.33
Forecasted Upside-3.61% Downside2.00% Upside-9.56% Downside-7.78% Downside
Consensus RatingHoldHoldHoldHold

NVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Novartis Stock vs. The Competition

TypeNovartisHealthcare CompaniesBroader Market
Consensus Rating Score
2.20
2.32
2.53
Consensus RatingHoldHoldModerate Buy
Predicted Upside-3.61% Downside1,400.11% Upside16.92% Upside
News Sentiment Rating
Positive News

See Recent NVS News
Neutral News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/22/2026
Weiss Ratings logo
Weiss Ratings
3 of 5 stars
 Reiterated RatingBuy (B)
10/6/2026
Morgan Stanley logo
Morgan Stanley
3 of 5 stars
Reiterated RatingOverweight$156.00+10.81%
9/21/2026 Reiterated RatingSell
9/17/2026 Reiterated RatingNeutral
9/17/2026 Reiterated RatingNeutral
9/11/2026 Lower TargetHold$147.00 ➝ $130.00-10.35%
9/10/2026UpgradeReduce ➝ Hold$123.00 ➝ $136.00-1.10%
9/8/2026 Initiated CoverageSector Perform
9/8/2026 Reiterated RatingBuy
8/9/2026 Reiterated RatingBuy
7/23/2026 Reiterated RatingNeutral
7/22/2026 Reiterated RatingBuy
7/22/2026 Reiterated RatingNeutral
4/28/2026 Reiterated RatingNeutral
4/28/2026 Reiterated RatingSell ➝ Neutral
3/11/2026 UpgradeHold ➝ Buy$180.00+11.36%
2/17/2026 Reiterated RatingHold
12/23/2025 DowngradeSell
10/29/2025Set TargetHold$126.00+2.09%
10/27/2025 DowngradeNeutral
4/15/2025UpgradeStrong-Buy
11/19/2024 Reiterated RatingBuy ➝ Hold
10/30/2024 Boost TargetMarket Perform$118.00 ➝ $120.00+8.53%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 02:55 PM ET.


Should I Buy Novartis Stock? NVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 23, 2026. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com.

Novartis
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Novartis AG:

  • Novartis AG recently presented six-year data for its breast cancer drug Kisqali, demonstrating a 19% reduction in the risk of death, which validates the long-term efficacy and commercial potential of a key asset in the company's oncology portfolio.
  • The company secured European Union approval for Cosentyx in the treatment of polymyalgia rheumatica, expanding the therapeutic reach of this immunology blockbuster and providing a new revenue stream in a competitive market.
  • Novartis AG is trading at a current stock price of $151.05, which is below the average analyst price target of $145.60, suggesting that the stock may be undervalued relative to Wall Street's consensus expectations for its future performance.
  • With a beta of 0.41, Novartis AG exhibits significantly lower volatility than the broader market, making it a defensive holding that can provide stability to a portfolio during periods of economic uncertainty or market turbulence.
  • The company offers a dividend yield of 2.00%, providing investors with a consistent income stream that can help offset market fluctuations and enhance total return over the long term.

Novartis
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Novartis AG for these reasons:

  • Novartis AG recently disclosed weaker-than-expected relapse data for its multiple sclerosis drug remibrutinib in Phase 3 trials, which could dampen investor confidence in the company's pipeline and future growth prospects in the neuroscience space.
  • The company halted its Phase 2 study of iptacopan in lupus nephritis, representing a setback in its renal and metabolic disease portfolio and potentially delaying the realization of revenue from this therapeutic area.
  • Novartis AG is scheduled to release its Q3 2026 earnings on October 27, 2026, and the stock has already declined as investors lock in gains ahead of the report, indicating potential near-term volatility and uncertainty surrounding the company's financial performance.
  • The consensus rating for Novartis AG is "Hold" with an average price target of $145.60, which is below the current stock price of $151.05, suggesting that analysts do not see significant upside potential in the stock at its current valuation.
  • Novartis AG has a debt-to-equity ratio of 0.89, which, while manageable, indicates a moderate level of leverage that could constrain the company's financial flexibility in a rising interest rate environment or during periods of economic stress.

NVS Forecast - Frequently Asked Questions

According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Novartis is $145.60, with a high forecast of $180.00 and a low forecast of $126.00.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings, 12 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.

According to analysts, Novartis's stock has a predicted downside of -3.61% based on their 12-month stock forecasts.

Over the previous 90 days, Novartis's stock had 2 upgrades and 1 downgrade by analysts.

Analysts like Novartis less than other "healthcare" companies. The consensus rating score for Novartis is 2.20 while the average consensus rating score for "healthcare" companies is 2.32. Learn more on how NVS compares to other companies.


MarketBeat monitors more than a dozen sources for Novartis analyst ratings, with the most recent rating issued on 10/22/2026.
From Our Partners